Jean-Paul Kress

Jean-Paul Kress

Chief Executive Officer at VOR BIOPHARMA INC.
59 year
Health Technology
Consumer Services
Distribution Services

Profile

Jean-Paul Kress currently works at Vor Biopharma, Inc., as Chairman, President & Chief Executive Officer from 2025, Syntimmune, Inc., as President & Director, and Sanofi, as Independent Director from 2025.
Dr. Kress also formerly worked at Sanofi Pasteur MSD SNC, as President & Chief Executive Officer from 2011 to 2015, MorphoSys AG, as CEO & Chairman-Management Board from 2019 to 2024, ERYTech Pharma SA, as Chairman from 2019 to 2023, Sarepta Therapeutics, Inc., as Independent Director from 2015 to 2017, Quantum Genomics SA, as Director from 2018 to 2019, Biogen, Inc., as President-International & Executive Vice President from 2017 to 2018, Genzyme Corp., as Senior Vice President & Head-North America from 2015 to 2017, Gilead Sciences SAS, as Vice President-US Sales & Marketing, and Abbott France SAS, as General Manager-Denmark.
Dr. Kress received his undergraduate degree in 1991 and graduate degree in 1992 from École Normale Supérieure and doctorate degree in 1991 from Faculté De Médecine Necker Enfants Malades Université.

Jean-Paul Kress active positions

CompaniesPositionStart
SANOFI Director/Board Member 2024-12-31
VOR BIOPHARMA INC. Chief Executive Officer 2025-06-24
President 2018-01-02

Former positions of Jean-Paul Kress

CompaniesPositionEnd
MORPHOSYS AG Chief Executive Officer 2024-06-05
Chairman 2023-06-22
QUANTUM GENOMICS Director/Board Member 2019-06-23
BIOGEN INC. Corporate Officer/Principal 2017-12-31
SAREPTA THERAPEUTICS, INC. Director/Board Member 2017-06-05
See the detail of Jean-Paul Kress's experience

Training of Jean-Paul Kress

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

55

1st degree connections

14

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies14

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Distribution Services

Health Technology

Distribution Services

Health Technology

Consumer Services

  1. Stock Market
  2. Insiders
  3. Jean-Paul Kress